Open Access
Table 2
Baseline characteristics of the study patients.
| Characteristics | Cytosorb group (n = 5) | Jafron group (n = 5) | Control group (n = 5) | p | |
|---|---|---|---|---|---|
| Demographic data | Age, years | 50.4 ± 9.2 | 50.6 ± 11.2 | 50.8 ± 17.5 | 0.44 |
| Male, n (%) | 5 (100%) | 4 (80%) | 3 (60%) | 0.18 | |
| BMI, kg/m2 | 26.8 ± 3.1 | 27.3 ± 2.6 | 26 ± 5.3 | 0.86 | |
| Comorbidities, n (%) | Coronary artery disease | 2 (40%) | 2 (40%) | 1 (20%) | |
| Atrial fibrillation | 1 (10%) | ||||
| Diabetes | 2 (40%) | 1 (20%) | 3 (60%) | ||
| Stroke | 2 (40%) | 1 (20%) | 2 (40%) | ||
| Infection | 1 (20%) | 2 (40%) | 1 (20%) | ||
| Myocardial infarction | 2 (40%) | 2 (40%) | 2 (40%) | ||
| Pulmonary hypertension | 1 (20%) | 2 (40%) | 1 (20%) | ||
| Primary diagnosis, n (%) | Ischemic cardiomyopathy | 3 (60%) | 1 (20%) | 2 (40%) | |
| Dilated cardiomyopathy | 2 (40%) | 4 (80%) | 3 (60%) | ||
| Ejection fraction, % | 16 (14–21) | 15 (15–20) | 17 (16–22) | ||
| INTERMACS profile, n (%) | 1–2 | 2 (40%) | 3 (60%) | 2 (40%) | |
| Device strategy at the time of implantation, n (%) | Destination therapy | 5 (100%) | 5 (100%) | 5 (100%) |
Abbreviations: BMI, body mass index; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.